Chang Alan L, Miska Jason, Wainwright Derek A, Dey Mahua, Rivetta Claudia V, Yu Dou, Kanojia Deepak, Pituch Katarzyna C, Qiao Jian, Pytel Peter, Han Yu, Wu Meijing, Zhang Lingjiao, Horbinski Craig M, Ahmed Atique U, Lesniak Maciej S
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Committee on Cancer Biology, The University of Chicago, Chicago, Illinois.
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Cancer Res. 2016 Oct 1;76(19):5671-5682. doi: 10.1158/0008-5472.CAN-16-0144. Epub 2016 Aug 16.
In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). However, the mechanistic details of how Tregs and MDSCs are recruited in various tumors are not yet well understood. Here we report that macrophages and microglia within the glioma microenvironment produce CCL2, a chemokine that is critical for recruiting both CCR4 Treg and CCR2Ly-6C monocytic MDSCs in this disease setting. In murine gliomas, we established novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macrophages and microglia. Tumors grown in CCL2-deficient mice failed to maximally accrue Tregs and monocytic MDSCs. In mixed-bone marrow chimera assays, we found that CCR4-deficient Treg and CCR2-deficient monocytic MDSCs were defective in glioma accumulation. Furthermore, administration of a small-molecule antagonist of CCR4 improved median survival in the model. In clinical specimens of glioblastoma multiforme, elevated levels of CCL2 expression correlated with reduced overall survival of patients. Finally, we found that CD163-positive infiltrating macrophages were a major source of CCL2 in glioblastoma multiforme patients. Collectively, our findings show how glioma cells influence the tumor microenvironment to recruit potent effectors of immunosuppression that drive progression. Cancer Res; 76(19); 5671-82. ©2016 AACR.
在许多侵袭性癌症中,如多形性胶质母细胞瘤,调节性T细胞(Treg)和髓源性抑制细胞(MDSC)的积累所驱动的局部免疫抑制促进了肿瘤进展。然而,Treg和MDSC在各种肿瘤中被招募的机制细节尚未完全清楚。在此我们报告,胶质瘤微环境中的巨噬细胞和小胶质细胞产生CCL2,一种趋化因子,在这种疾病背景下,它对于招募CCR4 Treg和CCR2Ly-6C单核MDSC至关重要。在小鼠胶质瘤中,我们确定了肿瘤来源的CCL20和骨保护素在诱导巨噬细胞和小胶质细胞产生CCL2方面的新作用。在CCL2缺陷小鼠中生长的肿瘤无法最大限度地积累Treg和单核MDSC。在混合骨髓嵌合体试验中,我们发现CCR4缺陷的Treg和CCR2缺陷的单核MDSC在胶质瘤积累方面存在缺陷。此外,给予CCR4的小分子拮抗剂可提高该模型的中位生存期。在多形性胶质母细胞瘤的临床标本中,CCL2表达水平升高与患者总生存期缩短相关。最后,我们发现CD163阳性浸润巨噬细胞是多形性胶质母细胞瘤患者CCL2的主要来源。总的来说,我们的研究结果表明胶质瘤细胞如何影响肿瘤微环境以招募驱动肿瘤进展的强效免疫抑制效应细胞。《癌症研究》;76(19);5671 - 82。©2016美国癌症研究协会。